- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Flurotech Ltd (2): Flurotech to change name; arranges $22M equity financing | 1 | Stockwatch | ||
| Mi | FluroTech Ltd.: FluroTech, to be renamed Consolidated Aerospace Finance Corporation, Announces $22 Million Equity Financing | 97 | GlobeNewswire (Europe) | THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, May 01, 2024 (GLOBE NEWSWIRE) -- FluroTech Ltd. (TSXV: TEST.H) ("FluroTech")... ► Artikel lesen | |
| Mi | Flurotech Ltd (2): Flurotech 1,826,480 shares for debt | 1 | Stockwatch | ||
| Mi | Flurotech Ltd (2): Flurotech 13,333,335-share private placement | 1 | Stockwatch | ||
| Di | Flurotech Ltd (2): Flurotech to settle $136,986 debt with 1.82M shares | 2 | Stockwatch | ||
| Di | FluroTech Ltd.: FluroTech Announces Debt Settlement Agreement | 366 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 30, 2024) - FluroTech Ltd. (TSXV: TEST.H) ("FluroTech" or the "Company") is pleased to announce that it has entered into a debt settlement agreement (the "Debt... ► Artikel lesen | |
| 26.04. | Flurotech Ltd (2): Flurotech completes $1-million private placement | 1 | Stockwatch | ||
| 26.04. | FluroTech Ltd.: FluroTech Announces Closing of Oversubscribed Private Placement Financing | 601 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 26, 2024) - FluroTech Ltd. (TSXV: TEST.H) ("FluroTech" or the "Company") is pleased to announce, further to its news release dated April 19, 2024, that it... ► Artikel lesen | |
| 23.04. | Flurotech Ltd (1): Flurotech to remain halted | 1 | Stockwatch | ||
| 20.04. | Flurotech Ltd: Flurotech 1:15 rollback | 2 | Stockwatch | ||
| 20.04. | Flurotech Ltd: Flurotech enters definitive deal for buy of GS Heli | 3 | Stockwatch | ||
| 20.04. | FluroTech Ltd.: FluroTech and GS Heli Announce Execution of Definitive Agreement | 1.475 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 19, 2024) - FluroTech Ltd. (TSXV: TEST.H) ("FluroTech" or the "Company"), to be renamed Consolidated Aerospace Finance Corporation ("CAFC") pursuant to the... ► Artikel lesen | |
| 12.03. | Flurotech Ltd: Flurotech amends LOI to acquire Great Slave | 1 | Stockwatch | ||
| 12.03. | FluroTech Ltd.: FluroTech Enters into a Non-Binding Letter of Intent for Change of Business Transaction | 452 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 11, 2024) - FluroTech Ltd. (TSXV: TEST.H) ("FluroTech" or the "Company") and Great Slave Helicopters 2018 Ltd. ("GS Heli") are pleased to announce that further... ► Artikel lesen | |
| 21.12.23 | Flurotech Ltd: Flurotech enters LOI with Great Slave for RTO | 1 | Stockwatch | ||
| 21.12.23 | FluroTech Ltd.: FluroTech Enters into Non-Binding Letter of Intent for Reverse Take-Over Transaction and Officer and Board Appointment | 565 | Newsfile | Toronto, Ontario--(Newsfile Corp. - December 21, 2023) - FluroTech Ltd. (TSXV: TEST.H) ("FluroTech" or the "Company") and Great Slave Helicopters 2018 Ltd. ("GS Heli") are pleased to announce that... ► Artikel lesen | |
| 21.12.23 | Flurotech Ltd: Flurotech halted at the open | 1 | Stockwatch | ||
| 06.11.23 | Danny Dalla-Longa Announces Filing of Early Warning Report Related to FluroTech Ltd | 253 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 6, 2023) - Danny Dalla-Longa announced today that on November 3, 2023 he acquired, directly or indirectly, beneficial ownership, control or direction over... ► Artikel lesen | |
| 27.10.23 | FluroTech Ltd. Announces Transfer to NEX Exchange | 308 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 27, 2023) - FluroTech Ltd. (TSXV: TEST) (OTC Pink: FLURF) ("FluroTech" or the "Company") announces that effective October 30, 2023 the Company's listing... ► Artikel lesen | |
| 06.10.23 | FluroTech Ltd. Announces Termination of Letter of Intent with Renewable Geo Resources Ltd. | 351 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 6, 2023) - FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) ("FluroTech" or the "Company") announces that the previously announced letter of intent, as amended... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,940 | +0,90 % | Qiagen bekräftigt Prognose für 2024 - erste Expertenstimmen | Das Biotech-Unternehmen Qiagen meldet für das erste Quartal 2024 einen Umsatzrückgang von 485,4 Millionen Dollar auf 458,8 Millionen Dollar. Das Betriebsergebnis ist leicht gefallen und liegt bei 94... ► Artikel lesen | |
| EVOTEC | 9,760 | -1,36 % | Delivery Hero, pbb, Evotec, K+S, TAG Immobilien, Varta und Co. - Aktien-Positionen der Shortseller | Wer Aktien leer verkauft, das sogenannte Shortselling, muss Transparenzpflichten erfüllen. Wir werfen einen Blick auf aktuelle Shortseller-Meldungen. Geregelt sind diese in der EU-Leerverkaufsverordnung... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 45,110 | +4,06 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 37,400 | +3,03 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 8,000 | -6,98 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in... ► Artikel lesen | |
| DYNE THERAPEUTICS | 26,080 | +0,31 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,840 | +0,57 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| NUVALENT | 70,35 | -2,95 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| CG ONCOLOGY | 36,270 | -8,18 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
| JANUX THERAPEUTICS | 64,78 | +3,76 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| ANNEXON | 4,880 | +4,72 % | Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? | ||
| SANA BIOTECHNOLOGY | 10,440 | +6,75 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory... ► Artikel lesen | |
| CABALETTA BIO | 12,390 | -1,67 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 27,270 | +2,83 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 26,450 | +3,40 % | Navigating 7 Analyst Ratings For Avidity Biosciences |
FLUROTECH LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
